Clinical Case of Drug Allergy to Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II

Background. Enzyme replacement therapy (ERT) with iduronate-2-sulfatase recombinant forms (idursulfase and idursulfase beta) is effective for the management of mucopolysaccharidosis type II (MPS II). Patients with Hunter syndrome require lifelong ERT that can negate endogenous enzyme deficiency. However, hypersensitivity reactions may occur during ERT, and they significantly complicate the implementation of vital therapy.

Clinical case description. This article describes clinical case of a child with hypersensitivity reaction to ERT. The patient with confirmed diagnosis of MPS II was administrated with idursulfase. Then, the drug was replaced with idursulfase beta due to the allergic reaction. Thus, even after the drug change, side effects maintained without sustained improvement with underlying glucocorticosteroids (GCS), antihistamines and with decreased infusion rate. Concerning the vital need to continue ERT, this patient with drug allergy to this pharmacotherapeutic group was further administered with combined therapy of cyclosporine and omalizumab. Personalised protocol for the administration of idursulfase beta with desensitization was developed. Such experience was firstly described In Russian patient.

Conclusion. The presented personalised combination therapy made it possible to prevent hypersensitivity reactions during ERT in the patient with MPS II.

1. Mukopolisakharidoz tip II: Clinical guidelines. Association of Medical Geneticists, Union of Pediatricians of Russia. Ministry of Health of Russia; 2019. (In Russ).

2. D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. Int J Mol Sci. 2020;21(4):1258. doi: https://doi.org/10.3390/ijms21041258

3. Wikman-Jorgensen PE, López Amoros A, Peris García J, et al. Enzyme replacement therapy for the treatment of Hunter disease: A systematic review with narrative synthesis and meta-analysis. Mol Genet Metab. 2020;131(1-2):206–210. doi: https://doi.org/10.1016/j.ymgme.2020.07.005

4. da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev. 2016;2(2):CD008185. doi: https://doi.org/10.1002/14651858.CD008185.pub4

5. Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfasetreated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2017;40(6):867–874. doi: https://doi.org/10.1007/s10545-017-0075-x

6. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465-473. doi: https://doi.org/10.1097/01.gim.0000232477.37660.fb

7. Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44(Suppl 2):120. doi: https://doi.org/10.1186/s13052-018-0562-1

8. Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99(1):18-25. doi: https://doi.org/10.1016/j.ymgme.2009.08.006

9. Muenzer J, Beck M, Giugliani R, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med. 2011;13(2):102–109. doi: https://doi.org/10.1097/GIM.0b013e318206786f

10. Muenzer J, Beck M, Eng CM, et al. Long-term, openlabeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95–101. doi: https://doi.org/10.1097/GIM.0b013e3181fea459

11. Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2):167– 174. doi: https://doi.org/10.1038/jhg.2016.133

12. Khodoun M, Strait R, Orekov T, et al. Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol. 2009;123(2):342–351. doi: https://doi.org/10.1016/j.jaci.2008.11.004

13. Khodoun MV, Strait R, Armstrong L, et al. Identification of markers that distinguish IgEfrom IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A. 2011;108(30):12413–12418. doi: https://doi.org/10.1073/pnas.1105695108

14. Arias K, Chu DK, Flader K, et al. Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice. J Allergy Clin Immunol. 2011;127(6):1552– 1561.e1. doi: https://doi.org/10.1016/j.jaci.2011.03.044

15. Vogler C, Levy B, Galvin NJ, et al. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to β-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res. 1999;45(6):838–844. doi: https://doi.org/10.1203/00006450-199906000-00010

16. Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124(6):e1228–1239. doi: https://doi.org/10.1542/peds.2008-0999

17. Sohn YB, Cho SY, Park SW, et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis. 2013;8:42. doi: https://doi.org/10.1186/1750-1172-8-42

18. Sohn YB, Cho SY, Lee J, et al. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome. Mol Genet Metab. 2015;114(2):156– 160. doi: https://doi.org/10.1016/j.ymgme.2014.08.009

19. Levina JG, Vashakmadze ND, Namazova-Baranova LS, et al. Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(6S):624–629. (In Russ). doi: https://doi.org/10.15690/vsp.v20i6S.2372

20. Ngu LH, Ong Peitee W, Leong HY, Chew HB. Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II. Mol Genet Metab Rep. 2017;12:28–32. doi: https://doi.org/10.1016/j.ymgmr.2017.05.002

21. Kruchina TK., Bruchikov KV., Novik GA. Experience of Idursulfase Beta Administration in the Child with Mucopolysaccharidosis Type II: Clinical Case. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(5):364–370. (In Russ). doi: https://doi.org/10.15690/vsp.v19i5.2212

22. Ensina LF, Felix MMR, da Cunha FS, Caubet JC. Desensitization to drugs in children. Allergol Immunopathol (Madr). 2022;50(2):48– 57. doi: https://doi.org/10.15586/aei.v50i2.539

23. Esenboga S, Akarsu A, Ocak M, et al. Safety and efficacy of rapid drug desensitization in children. Pediatr Allergy Immunol. 2022;33(3):e13759. doi: https://doi.org/10.1111/pai.13759

24. Serrano CD, Gomez JF. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome). J Investig Allergol Clin Immunol. 2011;21(7):571– 572.

25. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140(2):335–348. doi: https://doi.org/10.1016/j.jaci.2017.06.003

26. Matheu V, Franco A, Perez E, et al. Omalizumab for drug allergy. J Allergy Clin Immunol. 2007;120(6):1471–1472; author reply 1472–1473. doi: https://doi.org/10.1016/j.jaci.2007.07.037